CXCL10 and small cell lung carcinoma: In a similar study, the Chk1 inhibitor SRA737 in combination with low dose gemcitabine increased CCL5, IFN-β and CXCL10 mRNA expression in small cell lung cancer [46] again indicative of Chk1i activating a Type I IFN response.